SecBot SecBot
8-K ·Filed Nov 4, 2026

QURE

uniQure N.V.
BULLISH
Impact 7/10
Horizonmonths Processed12d 17h ago SEC0001104659-26-122362
8-K Item 2.02: Earnings release
Actionable Insight ▲ Bullish

The PDUFA date of May 1, 2027 is the key catalyst. Watch for confirmatory study enrollment updates and any FDA advisory committee meeting announcement. The UK MAA validation adds a second regulatory path.

DirectionBullish
Confidencehigh
Horizonmonths

AMT-130

▲ Bullish Named in this 8-K
Impact
Phase
Phase 1/2 (pivotal for accelerated approval)
Time to market
BLA submission planned for Q3 2026; FDA accelerated approval decision likely 6-10 months after submission (potentially H1 2027)
Next catalyst
None dated

What to watchThe BLA submission in Q3 2026 is the key near-term catalyst. The FDA has already aligned on the submission package, but final acceptance and review timelines remain to be seen. Watch for the official BLA filing announcement, PDUFA date assignment, and any FDA Advisory Committee meeting. The $225M June 2026 offering funds commercialization readiness but added ~8% dilution. Analysts are bullish (16 buy vs 5 hold, mean PT ~$64.59, ~47% upside from ~$44).

Price Chart

Loading chart...

Executive Summary

The headline event is the FDA granting Priority Review of the BLA for AMT-130 (ifezuntirgene inilparvovec) in Huntington's disease, with a PDUFA date of May 1, 2027, and alignment on a confirmatory study design. Cash of $768.4M is expected to fund operations into 2030.

Key Financial Metrics

Revenue
$5.2M
est $5.4M · -3.8% · +40.4% YoY

Key Facts

  • FDA granted Priority Review of BLA for AMT-130 (ifezuntirgene inilparvovec) in Huntington's disease; PDUFA target action date May 1, 2027
  • Aligned with FDA on confirmatory study design: randomized, standard-of-care-controlled trial of ~200 patients, 2:1 randomization, TFC primary endpoint at 36 months; U.S. patient screening expected by end of 2026
  • Q3 2026 revenue $5.2M vs $3.7M in Q3 2025 (increase of $1.5M due to higher license revenue)
  • Cash, cash equivalents and investment securities of $768.4M as of September 30, 2026, expected to fund operations into 2030
  • UK MHRA validated MAA for AMT-130 in Q3 2026
  • 48-month data from 12 high-dose patients showed 61% slowing on TFC (nominal p=0.008) vs external control
  • 36-month analysis of all 15 high-dose patients showed 80% slowing on cUHDRS (nominal p=0.005) and 67% slowing on TFC (nominal p=0.011)

Financial Impact

Q3 2026 revenue $5.2M (up 40.4% YoY), net loss $61.2M ($0.88/share) vs $80.5M ($1.38/share) in prior year; cash $768.4M

revenuenet losscash position

Risk Factors

  • BLA is under accelerated approval pathway; FDA may require additional data or a confirmatory study that could delay or prevent approval
  • Clinical data is from a small Phase I/II study (51 patients total) with non-significant primary endpoint (cUHDRS p=0.144 at 48 months)
  • Pre-revenue company with no approved products in its pipeline; valuation depends entirely on regulatory and clinical success
  • Cash burn remains high ($61.2M net loss in Q3 alone) despite $768.4M cash position

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
85% bullish (20 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001104659-26-122362
Document: tm2628930d1_8k.htm0001104659-26-122362
Document: 0001104659-26-122362-index-headers.html0001104659-26-122362
Document: 0001104659-26-122362-index.html0001104659-26-122362
Document: 0001104659-26-122362.txt0001104659-26-122362
8-K Data (Synthetic)0001104659-26-122362

Track record

38 reports on QURE

Performance horizon

6 of 11 bullish or bearish reports moved the stock their way by T+1. Best: +27.15% at T+20 after the Jul 29, 2026 report. 8 of 11 went positive at some point.

Filters
  1. Nov 6, 202610d ago 144 Neutral 2/10 Entry $22.79 to $22.71 Now $21.88 −3.99% ▼ −0.35% +0.02% vs SPY
  2. Nov 4, 202612d ago 8-K Bullish 7/10 Viewing No price data
  3. Nov 4, 202612d ago Press Release Neutral 6/10 Entry $23.03 to $21.01 Now $21.88 −4.99% ▼ −8.77% −4.36% vs SPY
  4. Nov 2, 202614d ago 8-K Bullish 7/10 Entry $22.97 to $23.87 Now $21.88 −4.75% ▲ +3.92% +3.62% vs SPY
  5. Nov 2, 202614d ago Press Release Bullish 7/10 Entry $22.97 to $23.87 Now $21.88 −4.75% ▲ +3.92% +3.62% vs SPY
  6. Oct 16, 20264w ago SC 13G/A Neutral 3/10 Entry $21.78 to $22.20 Now $21.88 +0.46% ▲ +1.93% +1.51% vs SPY
  7. Sep 2, 202610w ago 8-K Bullish 7/10 Entry $46.23 to $44.86 Now $21.88 −52.67% ▼ −2.96% −4.01% vs SPY
  8. Jul 29, 202615w ago 8-K Bullish 8/10 Entry $40.07 to $42.19 Now $21.88 −45.40% ▲ +5.29% +3.61% vs SPY
  9. Jul 7, 202619w ago Insider Cluster Bearish 5/10 Entry $41.41 to $43.49 Now $21.88 +47.16% ▼ −5.02% −5.33% vs SPY
  10. Jul 2, 202619w ago Insider Cluster Bearish 4/10 Entry $41.81 to $41.36 Now $21.88 +47.67% ▲ +1.08% +1.95% vs SPY
Showing 10 of 38

US Market Status

Market Closed · Opens in 8h 20m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 4, 2026